Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) supporting its plans for an adaptive Phase 2 field study of TNX-4800, a long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. This regulatory feedback is a critical milestone for the company as it advances a potential new approach to Lyme disease prevention.
The planned study is a randomized, placebo-controlled trial expected to enroll approximately 3,300 adults over two Lyme disease seasons. The study aims to evaluate the efficacy of TNX-4800 in preventing Lyme disease through six months after dosing, with manufacturing of the investigational product on track for delivery to study sites in the first quarter of 2027. Tonix is developing TNX-4800 as a seasonal immunopreventative administered as two subcutaneous injections three months apart, with the potential to provide protection throughout the U.S. Lyme disease season.
Lyme disease is the most common vector-borne illness in the United States, with an estimated 476,000 cases annually. Current prevention strategies rely primarily on personal protective measures and tick control, and there is no vaccine available for humans. TNX-4800, if successful, could offer a novel preventive option that addresses a significant unmet medical need, particularly for individuals in high-risk areas.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s CNS portfolio includes TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years, and acute migraine products Zembrace® SymTouch® and Tosymra®. Tonix is also exploring TONMYA's potential in major depressive disorder and acute stress disorder through Phase 2 trials. Additionally, the CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease.
In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The company’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The FDA's feedback provides a clear regulatory pathway for TNX-4800, which is a significant step toward potentially bringing a new preventive option to market. The company's progress on manufacturing and study design indicates a commitment to advancing this important public health initiative. For more information, visit https://ibn.fm/pe0eP.
